How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,851 results for

Tongue Carcinoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1641. Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Thryoid Gland Nonmedullary Carcinoma Thyroid Gland Medullary Carcinoma Tongue Cancer Untreated Metastatic Squamous Neck Cancer With Occult Primary Drug: gefitinib Not Applicable Detailed Description: PRIMARY OBJECTIVES: I. To assess the feasibility of enrolling patients ages 75 years or older and 50 years and younger with metastatic or unresectable head and neck cancer or non-small cell lung cancer (...) Laryngeal Diseases Thyroid Neoplasms Laryngeal Neoplasms Oropharyngeal Neoplasms Carcinoma, Verrucous Carcinoma, Basal Cell Salivary Gland Neoplasms Nasopharyngeal Carcinoma Papilloma Paranasal Sinus Neoplasms Carcinoma, Adenoid Cystic Neoplasms, Unknown Primary Carcinoma, Mucoepidermoid Granuloma Esthesioneuroblastoma, Olfactory Papilloma, Inverted Thyroid Cancer, Papillary Tongue Neoplasms Thyroid Carcinoma, Anaplastic Adenocarcinoma, Follicular Carcinoma, Medullary Carcinoma, Neuroendocrine

2003 Clinical Trials

1642. Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

with analgesics d) not typical for pre-existing headaches Ischemic retinopathy, optic neuropathy, or visual loss Tongue/jaw pain and/or claudication TIA or stroke Extremity claudication Musculoskeletal symptoms + ESR of > 40 mm/hr or CRP above the normal limit Malaise/fatigue + ESR of > 40 mm/hr or CRP above the normal limit Other symptoms/signs due to GCA/TAK requiring reinstitution/increase in GC Imaging features • Development of new vascular stenosis or aneurysm in new vascular territories as seen by MRI (...) mg/dL or creatinine clearance of 20 ml/min or less Other uncontrolled disease that could prevent safe study completion History of any malignant neoplasm except adequately treated basal or squamous cell carcinoma of the skin or solid tumors treated with curative therapy and disease-free for at least 5 years Receipt of an investigational agent or device within 30 days prior to study entry A live vaccination within 4 weeks prior to study entry Presence of a positive tuberculin skin test

2007 Clinical Trials

1643. Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Carcinoma Stage IV Oral Cavity Verrucous Carcinoma Stage IV Oropharyngeal Squamous Cell Carcinoma Tongue Carcinoma Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary Drug: Cediranib Maleate Other: Laboratory Biomarker Analysis Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. Determine the objective clinical response in patients with recurrent or newly diagnosed metastatic squamous cell carcinoma of the head and neck treated with AZD2171 (cediranib maleate). SECONDARY OBJECTIVES (...) or disease Intervention/treatment Phase Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Laryngeal Verrucous Carcinoma Recurrent Lip and Oral Cavity Squamous Cell Carcinoma Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma Recurrent Oral Cavity Verrucous Carcinoma Recurrent Oropharyngeal Squamous

2007 Clinical Trials

1644. Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Pancreatic Cancer Stage IV Rectal Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Tongue (...) . Erlotinib hydrochloride and cetuximab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with cetuximab may kill more tumor cells. Condition or disease Intervention/treatment Phase Adenocarcinoma of the Colon Adenocarcinoma of the Rectum Advanced Adult Primary Liver Cancer Carcinoma of the Appendix Gastrointestinal Stromal Tumor Metastatic Gastrointestinal Carcinoid Tumor Metastatic Squamous Neck Cancer With Occult Primary Recurrent

2006 Clinical Trials

1645. Neck Surgery in Treating Patients With Early-Stage Oral Cancer

carcinoma of the lip and oral cavity tongue cancer Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Squamous Cell Head and Neck Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms by Site (...) with stage I-II oral cavity squamous cell carcinoma (SCC) improves survival, disease-free survival, and loco-regional disease control rates. To determine how SEND and complex reconstruction affect quality of life and mental health. To determine whether the use of SEND on all patients presenting with stage I-II oral cavity SCC represents a cost-effective use of resources. OUTLINE: This is a multicenter study. Patients are stratified by age (< 40 vs 40-64 vs ≥ 65 years of age), tumor stage (T1 vs T2

2007 Clinical Trials

1646. A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia

. Circumferential Barrett's metaplasia of at least 1cm in length (≥C1M1) or a tongue of Barrett's metaplasia of at least 2cm in length (≥C0M2) (irrespective of the presence now or historically of histologically proven intestinal metaplasia). Able to give written informed consent. WHO performance status of 0 or 1 i.e. fully active and self-caring. EXCLUSION CRITERIA High grade dysplasia or carcinoma at enrolment. Medical conditions which would make completing endoscopies or completing the trial difficult

2006 Clinical Trials

1647. Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment

glands in patients with HNSCC. Secondary Objectives: To establish a parotid gland dose volume histogram (DVH) versus measured flow relationship in this patient population: When the mean dose is < 24-26 Gy (shift recovery time to left) When the mean dose is > 24-26 Gy (DVH shift) To observe mucositis in the following lower dose RT areas: Upper lip Lower lip Right cheek Left cheek Right ventral and lateral tongue Left ventral and lateral tongue Floor of the mouth Soft palate Hard palate. To observe (...) , III, IV (TX, T1-T2, favorable T3 (exophytic) N0-N2b, M0), small volume primary and nodal, not requiring chemotherapy during RT (i.e., induction chemo is acceptable as well as concurrent biological therapy e.g., Cetuximab), squamous cell carcinoma (AJCC Staging of HNSCC). Lymph nodes bilaterally of the neck are at risk for metastatic disease and require irradiation per clinical judgment. Post-operative Patients: Histology confirmed oral cavity, oropharynx, larynx and hypopharynx squamous cell

2006 Clinical Trials

1648. Zinc Supplements in Lowering Cadmium Levels in Smokers

, 2017 Last Verified: September 2015 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Wake Forest University Health Sciences: renal cell carcinoma bladder cancer cervical cancer esophageal cancer gastric cancer adult acute myeloid leukemia pancreatic cancer hypopharyngeal cancer lip and oral cavity cancer laryngeal cancer nasopharyngeal cancer oropharyngeal cancer paranasal sinus and nasal (...) cavity cancer non-small cell lung cancer small cell lung cancer adult primary liver cancer tongue cancer tobacco use disorder Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Pancreatic Neoplasms Stomach Neoplasms Head and Neck Neoplasms Uterine Cervical Neoplasms Urinary Bladder Neoplasms Esophageal Neoplasms Liver Neoplasms Kidney Neoplasms Tobacco Use Disorder Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract

2006 Clinical Trials

1649. Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

or histologically confirmed index oral premalignant lesion (excluding carcinoma in situ), 12mm or greater in size that has not been biopsied in the past 6 weeks; each index lesion must be either a: dysplastic measurable leukoplakia or erythroplakia in the oral cavity or accessible oropharynx, or hyperplastic leukoplakia of high-risk sites, lateral and ventral tongue and floor of mouth The subject's life expectancy is > 12 weeks and Karnofsky performance score is 70-100% Hemoglobin and hematocrit levels above (...) ; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately and will be removed from the trial Ability to understand and the willingness to sign a written informed consent document The subject is of New York Heart Association (NYHA) Class 1 to 4 cardiac status Exclusion Criteria: The subject has active cancer or carcinoma in situ of the head and neck The subject has a contraindication to biopsy The subject has any

2006 Clinical Trials

1650. Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

: January 30, 2013 Last Update Posted: March 29, 2016 Last Verified: March 2016 Keywords provided by Fox Chase Cancer Center: bladder cancer cervical cancer esophageal cancer gastric cancer renal cell carcinoma adult primary liver cancer non-small cell lung cancer small cell lung cancer pancreatic cancer hypopharyngeal cancer laryngeal cancer lip and oral cavity cancer nasopharyngeal cancer oropharyngeal cancer paranasal sinus and nasal cavity cancer adult acute myeloid leukemia tongue cancer tobacco

2006 Clinical Trials

1651. Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients must have, or have previously had, stage I (T1NO) or stage II (T2NO) squamous cell carcinoma of the head and neck. Tumor sites include oral cavity (buccal mucosal, gingival, floor of mouth, dorsal/ventral tongue, pharyngeal wall), oropharynx, larynx (glottis, supraglottis, subglottis, epiglottis) hypopharynx, paranasal sinus and nasal cavity. May have oral pre-malignant lesions (i.e., hyperplasia, dysplasia, carcinoma in situ (...) Institute (NCI) Information provided by (Responsible Party): Dong Shin, Emory University Study Details Study Description Go to Brief Summary: This is a phase I study of second primary tumor prevention in early stage (stage I/II) patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN). Condition or disease Intervention/treatment Phase Head and Neck Cancer Drug: Erlotinib Drug: Celecoxib Phase 1 Detailed Description: This is a phase I study of second primary tumor prevention in early

2006 Clinical Trials

1652. Evaluation of swallowing function after intraoral soft tissue reconstruction with microvascular free flaps. (PubMed)

was used to assess tongue mobility and abnormalities of swallowing function. All patients who underwent reconstruction with LUFF or RFFF free flaps had decreased tongue mobility, except for the tip of the tongue. Patients who underwent anterior or posterior resection had greater decreases in tongue mobility than those who underwent medial resection. Swallowing impairment was similar in patients with LUFFs and those with RFFFs. Anterior resection of the oral cavity had a significant negative effect (...) on swallowing function. Silent aspiration occurred in five patients. In conclusion the resection site affected swallowing function, but the type of flap did not, in patients with oral carcinoma, who underwent tumour resection with reconstruction

2003 International Journal of Oral and Maxillofacial Surgery

1653. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. (PubMed)

, or GAD65), and two had thyroperoxidase antibodies. Two patients had a history of cancer: one had active prostate adenocarcinoma, and the second had a remote history of tongue carcinoma. Cranial MRI demonstrated mesial temporal lobe abnormalities in all patients. One patient improved spontaneously, and six were treated with IV methylprednisolone. Three improved remarkably with treatment. At follow-up evaluation, one had no cognitive deficits, four had mild persistent short-term memory dysfunction

2004 Neurology

1654. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. (PubMed)

Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity. Here, we provide molecular evidence associated with the anti-metastatic effect of silibinin by showing a marked inhibition of the invasion and motility of SCC-4 tongue cancer cells, with 89% and 66.4% of inhibition, respectively, by 100 microM of silibinin. This effect was associated with a reduced expression of MMP-2 and u-PA (...) , together with an enhanced expression of TIMP-2 and PAI-1. Silibinin also exerted an inhibitory effect on the phosphorylation of ERK1/2. Additionally, pre-treatment of SCC-4 cancer cells with 10 and 20 microM of U0126, a specific MEK inhibitor, resulted in a reduced expression of MMP-2 (18.7 and 51.4%) and u-PA (19.2 and 48.9%) concomitantly with a marked inhibition of cell invasion (13.7 and 45.7%). Finally, silibinin was evidenced by its inhibition of the metastasis of Lewis lung carcinoma (LLC) cells

2006 Journal of Dental Research

1655. Early radiation-induced malignant fibrous histiocytoma of the oral cavity. (PubMed)

years after radiation therapy. The primary tumour was classified as a well differentiated squamous cell carcinoma of the right rim of the tongue. Primary therapy was surgical resection of the tumour and post-operative radiation with 50 Gy. Five and a half years later, the patient developed a rapidly progressing MFH within the field of radiation.

2003 Journal of Laryngology & Otology

1656. Multidimensional assessment of voice and speech after supracricoid laryngectomy with cricohyoidopexy. (PubMed)

with cricohyoidopexy for primary laryngeal squamous cell carcinoma were included into the study. Vocal function was investigated by means or videolaryngostroboscopy. Voice quality was assessed by means of objective acoustic analysis and subjective perceptual ratings by trained raters. Aberrant, incompetent, and rough mucosal wave was observed in the anterior and superior surfaces of arytenoids(s), the inferior part of tongue base and the lateral walls of the hypopharynx. The acoustic parameters were found (...) Multidimensional assessment of voice and speech after supracricoid laryngectomy with cricohyoidopexy. This study was designed: to evaluate the vocal function in the patients with supracricoid laryngectomy (SCL) compared with normal subjects; to determine the factors affecting voice (such as number of arytenoid(s) preserved and movement of larynx and tongue base); and to determine the correlations between videolaryngostroboscopy, acoustic and perceptual parameters. Ten patients who underwent SCL

2004 Journal of Laryngology & Otology

1657. Osteoradionecrosis of the hyoid presenting as a cause of intractable neck pain following radiotherapy and the role of magnetic resonance image scanning to aid diagnosis. (PubMed)

Osteoradionecrosis of the hyoid presenting as a cause of intractable neck pain following radiotherapy and the role of magnetic resonance image scanning to aid diagnosis. Osteoradionecrosis of the hyoid has been reported rarely in the worldwide literature. We present the case of a 56-year-old gentleman who presented with intractable neck pain, following surgery and radiotherapy for a T(2)N(2c)M(0) tongue base carcinoma, to highlight the need to consider osteoradionecrosis of the hyoid rather (...) than recurrence of the carcinoma as the cause of such symptoms. The previously unreported appearance of osteoradionecrosis of the hyoid on a magnetic resonance image (MRI) scan and the use of this investigation to aid diagnosis is discussed.

2003 Journal of Laryngology & Otology

1658. Sclerosing rhabdomyosarcoma: a rare variant with predilection for the head and neck. (PubMed)

have reported the case of a 66-year-old woman with a 35-year history of heavy cigarette smoking and daily alcohol consumption and a 2-month history of progressive dysphagia and dysarthria secondary to an enlarging tongue mass. Urgent tracheotomy was performed for impending respiratory embarrassment. Direct laryngoscopy revealed a bulky, exophytic mass involving the base of tongue. Specimens were obtained and submitted for analysis.Initial frozen-section analysis of the specimens favored carcinoma (...) of rhabdomyosarcoma that has a predilection for the head and neck. The clinical presentation may mimic carcinoma. The otolaryngologist-head and neck surgeon must be familiar with this disease entity.

2005 Laryngoscope

1659. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. (PubMed)

and antitumor effect of intratumoral cisplatin. Fourteen patients with locally recurrent head and neck tumors (median age, 58.7 years) were included in this phase 2 trial. Recurrent tumors (squamous cell carcinomas) were located on the tongue, oral pharynx, or cervical nodes. Prior therapy was surgery and/or radiotherapy with or without intravenous chemotherapy. Inclusion criteria included an Eastern Cooperative Oncology Group/World Health Organization performance status of 0, 1, or 2, an anticipated

2004 Rhinology and Laryngology

1660. Radiation following surgery for oral cancer: impact on local control. (PubMed)

undergoing surgical therapy alone for squamous cell carcinoma of the oral cavity.Retrospective chart.Previously untreated patients with squamous cell carcinoma of the floor of mouth or oral tongue who were treated between 1974 and 1998 were eligible for study. A minimum follow-up of 2 years was required. Tumor site, stage, and RT data were correlated with local control.Patients with missing or incomplete data and those lost to follow-up or dead as a result of intercurrent disease with follow-up of less (...) Radiation following surgery for oral cancer: impact on local control. The use of postoperative radiation therapy (RT) is commonly used in the treatment of patients with high-risk squamous cell carcinoma of the head and neck. However, few data exist that quantitate the incremental benefit of RT when administered following surgery. The retrospective study was designed to measure the incremental benefit of adjuvant RT after surgery on control of the primary lesion when compared with patients

2003 Laryngoscope

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>